Treatment of melasma by a combination of intense pulsed light with advanced optimal pulse technology and human-like collagen repair dressing: A case series study
To observe the efficacy and safety of a combination of intense pulsed light (IPL) with advanced optimal pulse technology (AOPT) and human-like collagen repair dressing in the treatment of melasma. Ten patients with melasma were treated using IPL with AOPT once a month for a total of 8 times, and rec...
Saved in:
| Published in | Medicine (Baltimore) Vol. 101; no. 31; p. e29492 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Lippincott Williams & Wilkins
05.08.2022
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1536-5964 0025-7974 1536-5964 |
| DOI | 10.1097/MD.0000000000029492 |
Cover
| Abstract | To observe the efficacy and safety of a combination of intense pulsed light (IPL) with advanced optimal pulse technology (AOPT) and human-like collagen repair dressing in the treatment of melasma. Ten patients with melasma were treated using IPL with AOPT once a month for a total of 8 times, and received the treatment of external human-like collagen repair dressing after each operation. The efficacy was evaluated with the modified Melasma Area Severity Index (mMASI) score and satisfaction score, respectively, before treatment, after each treatment and at 4 months after the end of the whole treatment course.
The melasma was significantly lightened in all 10 patients after 8 times of treatments. The mMASI score before treatment was (8.6 ± 3.8) points, which decreased significantly to (5.1 ± 2.7) points after 8 times of treatments, and there was a significant difference in mMASI score between before and after 8 times of treatments (
P
= .001). The mMASI score was (3.3 ± 2.2) points at 4 months after the end of whole treatment course, and there was no significant difference in mMASI score between after 8 times of treatments and 4 months after the end of whole treatment course (
P
> .05). The satisfaction score was (7.2 ± 1.4) points after 8 times of treatments and (7.1 ± 1.4) points at 4 months after the end of whole treatment course, there was no significant difference in satisfaction score between after 8 times of treatments and 4 months after the end of whole treatment course (
P
> .05).
A combination of IPL with AOPT and human-like collagen repair dressing can effectively decrease the severity of melasma, and is associated with a higher patient satisfaction score and a lower risk of relapse after discontinuation of treatment. |
|---|---|
| AbstractList | To observe the efficacy and safety of a combination of intense pulsed light (IPL) with advanced optimal pulse technology (AOPT) and human-like collagen repair dressing in the treatment of melasma.
Ten patients with melasma were treated using IPL with AOPT once a month for a total of 8 times, and received the treatment of external human-like collagen repair dressing after each operation. The efficacy was evaluated with the modified Melasma Area Severity Index (mMASI) score and satisfaction score, respectively, before treatment, after each treatment and at 4 months after the end of the whole treatment course.
The melasma was significantly lightened in all 10 patients after 8 times of treatments. The mMASI score before treatment was (8.6 ± 3.8) points, which decreased significantly to (5.1 ± 2.7) points after 8 times of treatments, and there was a significant difference in mMASI score between before and after 8 times of treatments (
P
= .001). The mMASI score was (3.3 ± 2.2) points at 4 months after the end of whole treatment course, and there was no significant difference in mMASI score between after 8 times of treatments and 4 months after the end of whole treatment course (
P
> .05). The satisfaction score was (7.2 ± 1.4) points after 8 times of treatments and (7.1 ± 1.4) points at 4 months after the end of whole treatment course, there was no significant difference in satisfaction score between after 8 times of treatments and 4 months after the end of whole treatment course (
P
> .05).
A combination of IPL with AOPT and human-like collagen repair dressing can effectively decrease the severity of melasma, and is associated with a higher patient satisfaction score and a lower risk of relapse after discontinuation of treatment. To observe the efficacy and safety of a combination of intense pulsed light (IPL) with advanced optimal pulse technology (AOPT) and human-like collagen repair dressing in the treatment of melasma. Ten patients with melasma were treated using IPL with AOPT once a month for a total of 8 times, and received the treatment of external human-like collagen repair dressing after each operation. The efficacy was evaluated with the modified Melasma Area Severity Index (mMASI) score and satisfaction score, respectively, before treatment, after each treatment and at 4 months after the end of the whole treatment course. The melasma was significantly lightened in all 10 patients after 8 times of treatments. The mMASI score before treatment was (8.6 ± 3.8) points, which decreased significantly to (5.1 ± 2.7) points after 8 times of treatments, and there was a significant difference in mMASI score between before and after 8 times of treatments ( P = .001). The mMASI score was (3.3 ± 2.2) points at 4 months after the end of whole treatment course, and there was no significant difference in mMASI score between after 8 times of treatments and 4 months after the end of whole treatment course ( P > .05). The satisfaction score was (7.2 ± 1.4) points after 8 times of treatments and (7.1 ± 1.4) points at 4 months after the end of whole treatment course, there was no significant difference in satisfaction score between after 8 times of treatments and 4 months after the end of whole treatment course ( P > .05). A combination of IPL with AOPT and human-like collagen repair dressing can effectively decrease the severity of melasma, and is associated with a higher patient satisfaction score and a lower risk of relapse after discontinuation of treatment. To observe the efficacy and safety of a combination of intense pulsed light (IPL) with advanced optimal pulse technology (AOPT) and human-like collagen repair dressing in the treatment of melasma. Ten patients with melasma were treated using IPL with AOPT once a month for a total of 8 times, and received the treatment of external human-like collagen repair dressing after each operation. The efficacy was evaluated with the modified Melasma Area Severity Index (mMASI) score and satisfaction score, respectively, before treatment, after each treatment and at 4 months after the end of the whole treatment course. The melasma was significantly lightened in all 10 patients after 8 times of treatments. The mMASI score before treatment was (8.6 ± 3.8) points, which decreased significantly to (5.1 ± 2.7) points after 8 times of treatments, and there was a significant difference in mMASI score between before and after 8 times of treatments ( P = .001). The mMASI score was (3.3 ± 2.2) points at 4 months after the end of whole treatment course, and there was no significant difference in mMASI score between after 8 times of treatments and 4 months after the end of whole treatment course ( P > .05). The satisfaction score was (7.2 ± 1.4) points after 8 times of treatments and (7.1 ± 1.4) points at 4 months after the end of whole treatment course, there was no significant difference in satisfaction score between after 8 times of treatments and 4 months after the end of whole treatment course ( P > .05). A combination of IPL with AOPT and human-like collagen repair dressing can effectively decrease the severity of melasma, and is associated with a higher patient satisfaction score and a lower risk of relapse after discontinuation of treatment. To observe the efficacy and safety of a combination of intense pulsed light (IPL) with advanced optimal pulse technology (AOPT) and human-like collagen repair dressing in the treatment of melasma. Ten patients with melasma were treated using IPL with AOPT once a month for a total of 8 times, and received the treatment of external human-like collagen repair dressing after each operation. The efficacy was evaluated with the modified Melasma Area Severity Index (mMASI) score and satisfaction score, respectively, before treatment, after each treatment and at 4 months after the end of the whole treatment course. The melasma was significantly lightened in all 10 patients after 8 times of treatments. The mMASI score before treatment was (8.6 ± 3.8) points, which decreased significantly to (5.1 ± 2.7) points after 8 times of treatments, and there was a significant difference in mMASI score between before and after 8 times of treatments (P = .001). The mMASI score was (3.3 ± 2.2) points at 4 months after the end of whole treatment course, and there was no significant difference in mMASI score between after 8 times of treatments and 4 months after the end of whole treatment course (P > .05). The satisfaction score was (7.2 ± 1.4) points after 8 times of treatments and (7.1 ± 1.4) points at 4 months after the end of whole treatment course, there was no significant difference in satisfaction score between after 8 times of treatments and 4 months after the end of whole treatment course (P > .05). A combination of IPL with AOPT and human-like collagen repair dressing can effectively decrease the severity of melasma, and is associated with a higher patient satisfaction score and a lower risk of relapse after discontinuation of treatment.To observe the efficacy and safety of a combination of intense pulsed light (IPL) with advanced optimal pulse technology (AOPT) and human-like collagen repair dressing in the treatment of melasma. Ten patients with melasma were treated using IPL with AOPT once a month for a total of 8 times, and received the treatment of external human-like collagen repair dressing after each operation. The efficacy was evaluated with the modified Melasma Area Severity Index (mMASI) score and satisfaction score, respectively, before treatment, after each treatment and at 4 months after the end of the whole treatment course. The melasma was significantly lightened in all 10 patients after 8 times of treatments. The mMASI score before treatment was (8.6 ± 3.8) points, which decreased significantly to (5.1 ± 2.7) points after 8 times of treatments, and there was a significant difference in mMASI score between before and after 8 times of treatments (P = .001). The mMASI score was (3.3 ± 2.2) points at 4 months after the end of whole treatment course, and there was no significant difference in mMASI score between after 8 times of treatments and 4 months after the end of whole treatment course (P > .05). The satisfaction score was (7.2 ± 1.4) points after 8 times of treatments and (7.1 ± 1.4) points at 4 months after the end of whole treatment course, there was no significant difference in satisfaction score between after 8 times of treatments and 4 months after the end of whole treatment course (P > .05). A combination of IPL with AOPT and human-like collagen repair dressing can effectively decrease the severity of melasma, and is associated with a higher patient satisfaction score and a lower risk of relapse after discontinuation of treatment. To observe the efficacy and safety of a combination of intense pulsed light (IPL) with advanced optimal pulse technology (AOPT) and human-like collagen repair dressing in the treatment of melasma. Ten patients with melasma were treated using IPL with AOPT once a month for a total of 8 times, and received the treatment of external human-like collagen repair dressing after each operation. The efficacy was evaluated with the modified Melasma Area Severity Index (mMASI) score and satisfaction score, respectively, before treatment, after each treatment and at 4 months after the end of the whole treatment course. The melasma was significantly lightened in all 10 patients after 8 times of treatments. The mMASI score before treatment was (8.6 ± 3.8) points, which decreased significantly to (5.1 ± 2.7) points after 8 times of treatments, and there was a significant difference in mMASI score between before and after 8 times of treatments (P = .001). The mMASI score was (3.3 ± 2.2) points at 4 months after the end of whole treatment course, and there was no significant difference in mMASI score between after 8 times of treatments and 4 months after the end of whole treatment course (P > .05). The satisfaction score was (7.2 ± 1.4) points after 8 times of treatments and (7.1 ± 1.4) points at 4 months after the end of whole treatment course, there was no significant difference in satisfaction score between after 8 times of treatments and 4 months after the end of whole treatment course (P > .05). A combination of IPL with AOPT and human-like collagen repair dressing can effectively decrease the severity of melasma, and is associated with a higher patient satisfaction score and a lower risk of relapse after discontinuation of treatment. |
| Author | Chen, Juping Liu, Jun Wu, Jianhong |
| AuthorAffiliation | Affiliated Hospital of Yangzhou University, Yangzhou, People’s Republic of China |
| AuthorAffiliation_xml | – name: Affiliated Hospital of Yangzhou University, Yangzhou, People’s Republic of China |
| Author_xml | – sequence: 1 givenname: Juping surname: Chen fullname: Chen, Juping organization: Affiliated Hospital of Yangzhou University, Yangzhou, People’s Republic of China – sequence: 2 givenname: Jun surname: Liu fullname: Liu, Jun – sequence: 3 givenname: Jianhong surname: Wu fullname: Wu, Jianhong |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35945756$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kk1v1DAQhiNURD_gFyAhH7mkTPyRrDkgVS1fUisu5Ww5zuzG1LEX2-lqfw7_FHe3hdIDvtiaed9nNJ45rg588FhVrxs4bUB2764uTuHvoZJL-qw6agRrayFbfvDofVgdp_QDoGEd5S-qQyYkF51oj6pf1xF1ntBnEpZkQqfTpEm_JZqYMPXW62yDv8tZn9EnJOvZJRyIs6sxk43NI9HDrfamxMI620m7vYRkNKMPLqwKzA9knCfta2dvsJCd0yv0JOJa20iGiClZv3pPzojRxZowWkwk5XnYvqyeL3Xhvbq_T6rvnz5en3-pL799_np-dlkbLgBq1rMF14h9uzRgsO0olbLr-wVrGUMxNE0zUEo50JYjDK0WdCEZb3uQUktB2Un1Yc9dz_2EgylfErVT61hailsVtFX_Zrwd1SrcKslEs-igAN7eA2L4OWPKarLJYGnVY5iToh1AyxnspG8e1_pT5GEuRSD3AhNDShGXyti8G0UpbZ1qQN3tgLq6UE93oHjZE-8D_v8uvndtgssY042bNxjViNrlcScXnaQ1BUphAQLquwiw3780xdM |
| CitedBy_id | crossref_primary_10_1016_j_cjac_2024_100449 crossref_primary_10_1007_s10103_024_04098_9 crossref_primary_10_3389_fmed_2023_1286159 |
| Cites_doi | 10.1097/DSS.0000000000000974 10.5021/ad.2010.22.4.373 10.1111/j.1468-3083.2011.04337.x 10.1111/jocd.12911 10.1111/j.1468-3083.2009.03295.x 10.1111/jdv.12854 10.1111/jocd.12392 10.1016/j.msec.2016.05.108 10.4103/0019-5154.164415 10.1007/s13555-017-0195-0 10.3390/ijms17060824 10.1007/s13555-017-0194-1 10.3390/ijms19092668 10.1097/DAD.0b013e3181ef2d45 10.1111/ijd.14541 10.2340/00015555-2668 10.1038/jid.2015.332 10.1016/j.jdermsci.2007.01.009 10.1111/j.1365-2230.2008.02724.x 10.1016/S0190-9622(81)70071-9 |
| ContentType | Journal Article |
| Copyright | Lippincott Williams & Wilkins Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. 2022 |
| Copyright_xml | – notice: Lippincott Williams & Wilkins – notice: Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. – notice: Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. 2022 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1097/MD.0000000000029492 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1536-5964 |
| EndPage | e29492 |
| ExternalDocumentID | PMC9351870 35945756 10_1097_MD_0000000000029492 00005792-202208050-00050 |
| Genre | Journal Article |
| GroupedDBID | --- .-D .XZ .Z2 01R 0R~ 354 40H 4Q1 4Q2 4Q3 5GY 5RE 5VS 71W 77Y 7O~ AAAAV AAGIX AAHPQ AAIQE AAMOA AAQKA AARTV AASCR AAWTL AAXQO AAYEP ABASU ABBUW ABCQX ABDIG ABFRF ABOCM ABVCZ ABXVJ ABZAD ABZZY ACDDN ACEWG ACGFO ACGFS ACILI ACLDA ACWDW ACWRI ACXJB ACXNZ ACZKN ADGGA ADHPY ADNKB ADPDF AE6 AEFWE AENEX AFBFQ AFDTB AGOPY AHOMT AHQNM AHVBC AIJEX AINUH AJCLO AJIOK AJNWD AJNYG AJZMW AKCTQ AKULP ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AOQMC BQLVK CS3 DIWNM DU5 E.X EBS EEVPB ERAAH EX3 F2K F2L F2M F2N F5P FCALG FD6 FIJ FL- GNXGY GQDEL GROUPED_DOAJ H0~ HLJTE HYE HZ~ H~9 IKREB IKYAY IN~ IPNFZ JK3 JK8 K8S KD2 KMI KQ8 L-C N9A N~7 N~B O9- OAG OAH OB2 OHH OK1 OL1 OLB OLG OLH OLU OLV OLY OLZ OPUJH OUVQU OVD OVDNE OVEED OVIDH OVLEI OWV OWW OWZ OXXIT P2P RIG RLZ RPM RXW S4R S4S TAF TEORI TSPGW UNMZH V2I VVN W3M WOQ WOW X3V X3W XYM YFH YOC ZFV ZY1 AAYXX CITATION 8L- ACIJW AWKKM CGR CUY CVF ECM EIF NPM ODA 7X8 ADSXY 5PM |
| ID | FETCH-LOGICAL-c4500-3b384aeeb6fc0ce6722997bb83633e5d111d22240264e0d6a5289346b099a9523 |
| ISSN | 1536-5964 0025-7974 |
| IngestDate | Thu Aug 21 13:33:53 EDT 2025 Thu Sep 04 22:43:03 EDT 2025 Wed Feb 19 02:24:49 EST 2025 Tue Jul 01 05:04:45 EDT 2025 Thu Apr 24 23:08:13 EDT 2025 Fri May 16 03:56:26 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 31 |
| Language | English |
| License | Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c4500-3b384aeeb6fc0ce6722997bb83633e5d111d22240264e0d6a5289346b099a9523 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0001-9302-4842 |
| OpenAccessLink | http://dx.doi.org/10.1097/MD.0000000000029492 |
| PMID | 35945756 |
| PQID | 2700643070 |
| PQPubID | 23479 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_9351870 proquest_miscellaneous_2700643070 pubmed_primary_35945756 crossref_citationtrail_10_1097_MD_0000000000029492 crossref_primary_10_1097_MD_0000000000029492 wolterskluwer_health_00005792-202208050-00050 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-August-05 2022-08-05 2022-Aug-05 20220805 |
| PublicationDateYYYYMMDD | 2022-08-05 |
| PublicationDate_xml | – month: 08 year: 2022 text: 2022-August-05 day: 05 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Hagerstown, MD |
| PublicationTitle | Medicine (Baltimore) |
| PublicationTitleAlternate | Medicine (Baltimore) |
| PublicationYear | 2022 |
| Publisher | Lippincott Williams & Wilkins |
| Publisher_xml | – name: Lippincott Williams & Wilkins |
| References | Atefi (R14-20250504) 2017; 7 Hwang (R5-20250504) 2016; 17 Arya (R1-20250504) 2019; 58 Bernerd (R3-20250504) 2018; 19 Alamdari (R6-20250504) 2018; 17 Abou-Taleb (R20-20250504) 2017; 43 Chen (R15-20250504) 2008; 34 Elbuluk (R12-20250504) 2017; 7 Sirithanabadeekul (R16-20250504) 2015; 29 Ambrosetti (R21-20250504) 2015; 135 Kim (R11-20250504) 2007; 46 Fan (R17-20250504) 2016; 68 Ortonne (R4-20250504) 2009; 23 Ha (R7-20250504) 2012; 26 Cho (R13-20250504) 2017; 97 Kang (R10-20250504) 2010; 22 Betkerur (R2-20250504) 2015; 60 Sanchez (R18-20250504) 1981; 4 Castanedo-Cazares (R8-20250504) 2008; 33 Castanedo-Cázares (R9-20250504) 2011; 33 Dua (R19-20250504) 2019; 18 |
| References_xml | – volume: 43 start-page: 210 year: 2017 ident: R20-20250504 article-title: Reliability, validity, and sensitivity to change over time of the modified melasma area and severity index score publication-title: J Dermatol Surg doi: 10.1097/DSS.0000000000000974 – volume: 34 start-page: 693 year: 2008 ident: R15-20250504 article-title: Efficacy and safety of intense pulsed light in treatment of melasma in Chinese patients publication-title: Dermatol Surg – volume: 22 start-page: 373 year: 2010 ident: R10-20250504 article-title: What should be considered in treatment of melasma publication-title: Ann Dermatol doi: 10.5021/ad.2010.22.4.373 – volume: 26 start-page: 1533 year: 2012 ident: R7-20250504 article-title: Defective barrier function in melasma skin publication-title: J Eur Acad Dermatol Venereol doi: 10.1111/j.1468-3083.2011.04337.x – volume: 18 start-page: 1066 year: 2019 ident: R19-20250504 article-title: Role of broad-spectrum sunscreen alone in the improvement of melasma area severity index (MASI) and melasma quality of life index in melasma publication-title: J Cosmet Dermatol doi: 10.1111/jocd.12911 – volume: 23 start-page: 1254 year: 2009 ident: R4-20250504 article-title: A global survey of the role of ultraviolet radiation and hormonal influences in the development of melasma publication-title: J Eur Acad Dermatol Venereol doi: 10.1111/j.1468-3083.2009.03295.x – volume: 29 start-page: 1339 year: 2015 ident: R16-20250504 article-title: Low-fluence Q-switched Nd: YAG 1064-nm laser and intense pulsed light for the treatment of melasma publication-title: J Eur Acad Dermatol Venereol doi: 10.1111/jdv.12854 – volume: 17 start-page: 417 year: 2018 ident: R6-20250504 article-title: Evaluation of the serum zinc level in adult patients with melasma: is there a relationship with serum zinc deficiency and melasma? publication-title: J Cosmet Dermatol doi: 10.1111/jocd.12392 – volume: 68 start-page: 317 year: 2016 ident: R17-20250504 article-title: A novel smart injectable hydrogel prepared by microbial transglutaminase and human-like collagen: its characterization and biocompatibility publication-title: Mater Sci Eng C Mater Biol Appl doi: 10.1016/j.msec.2016.05.108 – volume: 60 start-page: 519 year: 2015 ident: R2-20250504 article-title: Clinico-epidemiological study and quality of life assessment in melasma publication-title: Indian J Dermatol doi: 10.4103/0019-5154.164415 – volume: 7 start-page: 417 year: 2017 ident: R14-20250504 article-title: Therapeutic effects of topical tranexamic acid in comparison with hydroquinone in treatment of women with melasma publication-title: Dermatol Ther (Heidelb) doi: 10.1007/s13555-017-0195-0 – volume: 17 start-page: 824 year: 2016 ident: R5-20250504 article-title: Heterogeneous pathology of melasma and its clinical implications publication-title: Int J Mol Sci doi: 10.3390/ijms17060824 – volume: 7 start-page: 305 year: 2017 ident: R12-20250504 article-title: Melasma: an up-to-date comprehensive review publication-title: Dermatol Ther (Heidelb) doi: 10.1007/s13555-017-0194-1 – volume: 19 start-page: 2668 year: 2018 ident: R3-20250504 article-title: Clinical and biological characterization of skin pigmentation diversity and its consequences on UV impact publication-title: Int J Mol Sci doi: 10.3390/ijms19092668 – volume: 33 start-page: 291 year: 2011 ident: R9-20250504 article-title: Histochemical and immunohistochemical study in melasma: evidence of damage in the basal membrane publication-title: Am J Dermatopathol doi: 10.1097/DAD.0b013e3181ef2d45 – volume: 58 start-page: 1305 year: 2019 ident: R1-20250504 article-title: Clinical and epidemiologic features of melasma: a multicentric cross-sectional study from India publication-title: Int J Dermatol doi: 10.1111/ijd.14541 – volume: 97 start-page: 776 year: 2017 ident: R13-20250504 article-title: Efficacy and safety of tranexamic acid in melasma: a meta-analysis and systematic review publication-title: Acta Derm Venereol doi: 10.2340/00015555-2668 – volume: 135 start-page: 3096 year: 2015 ident: R21-20250504 article-title: Endothelial cells promote pigmentation through endothelin receptor B activation publication-title: J Invest Dermatol doi: 10.1038/jid.2015.332 – volume: 46 start-page: 111 year: 2007 ident: R11-20250504 article-title: The vascular characteristics of melasma publication-title: J Dermatol Sci doi: 10.1016/j.jdermsci.2007.01.009 – volume: 33 start-page: 305 year: 2008 ident: R8-20250504 article-title: Solar elastosis and presence of mast cells as key features in the pathogenesis of melasma publication-title: Clin Exp Dermatol doi: 10.1111/j.1365-2230.2008.02724.x – volume: 4 start-page: 698 year: 1981 ident: R18-20250504 article-title: Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study publication-title: J Am Acad Dermatol doi: 10.1016/S0190-9622(81)70071-9 |
| SSID | ssj0013724 |
| Score | 2.4040895 |
| Snippet | To observe the efficacy and safety of a combination of intense pulsed light (IPL) with advanced optimal pulse technology (AOPT) and human-like collagen repair... |
| SourceID | pubmedcentral proquest pubmed crossref wolterskluwer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | e29492 |
| SubjectTerms | Bandages Collagen - therapeutic use Humans Intense Pulsed Light Therapy - adverse effects Melanosis - etiology Melanosis - therapy Observational Study Technology Treatment Outcome |
| Title | Treatment of melasma by a combination of intense pulsed light with advanced optimal pulse technology and human-like collagen repair dressing: A case series study |
| URI | https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00005792-202208050-00050 https://www.ncbi.nlm.nih.gov/pubmed/35945756 https://www.proquest.com/docview/2700643070 https://pubmed.ncbi.nlm.nih.gov/PMC9351870 |
| Volume | 101 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1tb9MwELbKJiEkhHgd5WUyEt9CRpvEScy3shZNSIUvG-xb5DiuVq1rqrXVNP4Nv4C_yJ3f2qzVxOiHqHJc19E98d35njsT8r5SshrFURzmQnXAQYF1kEejOARbgDMpM8m1pIff0qOT5OspO221_qyxlpaL8kD-2ppX8j9ShTaQK2bJ3kGyflBogO8gX7iChOH6bzL2LHEdJQdD-EKgPSmQKQ4urzcHx5qoroLZEjRhFUzQI7dpbY4DUMPacYFpWdglWPgddx1d0Cf5hZPxOXLbATgwI4w2iPFlUGkircma7gUSlGKAz67ma5Vr3YlRNo6PVu1nMYH_0yRfvxVx6DNFZk6hIlVovDSNHsY_TQMA-6y2_ey-Bbi8yLNgjaU2DRk3NcwP1JY2tz7b3Q4DRKszzHKrIp6Yo_Q2NIGpMDzsmwKV5uN7N-tu39CHnqXo4vPDfnFzkHtkN8oy5AXsfv8xGPRXgavMnKPsHsQVuuLZxy1zaRpDGx7OJlH34VWNJIr5uc6hWLOEjh-TR9aFoT2DxyekpaZPyX0n3Gfkt4clrUfUwpKW11TQNVjiPQtLamBJNSwpwpI6WFILS9OFrmBJAZZ0BUvqYEkNLKmD5SfaowhKakBJNSifk5Mvg-PDo9CeBBLKhHXAUCjjPBFKYWZaR6o0i8CKysoyj9M4VqwChV1FaJyCea86VSpYBHZ4kpbg_wjOovgF2ZnWU_WSUC5k3o0T0U0zleRSldUIVFjOsm5Xlrko2yRyIimkLZOPp7VMilvg0CYf_I9mpkrM7d3fOVkXsJpjiE5MVb2cF0gDAR8B9HCb7BnZ-wFjxhNwrtI2yRqo8B2wUnzzznR8pivG85h1cxwzbOCnMLnWen4s41GI7ym4kEwXm2CdV3d7rNfkwepFf0N2FpdL9RZM9kW5r7e69u3L8hfg6-hk |
| linkProvider | Ovid |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1ti9NAEF6kByqI-G59HUH6yWibzSZZoR9Km7Oelyq0552fwmaz1XJtUvqi-HP8p85skmo9FOyXFnabQmd25pmdZ2YYe54ZnU25y51QmTYGKGgHpTvlDmIBKbQOtLSSjkf-8MQ7OhNnFduCamGo-my9fElv1k7TB5qHQ4HhpHs0bo2i03E3b_XH_e6n1ofem8jeUxNLojXoFl-nm1ZvZPlXIpAu6oDrIiYStnqaQvsDXyAEaLCD9x-jaPAr3xCU428F9x0hfa_uTySDV_Gg7HFYvlzpSXffh10Aphf5lde-FZT7Xp9b6vtvDuzwBrteIU_olapyk10y-S12Oa5y67fZj0nNOYdiCguDsHqhIP0OCvAvwgDaypDWZpb2bmC5Rb-awZzie6ALXagZBVCgJVrgr9ktsNnd34PKM7BzAZ357NyAVUPUYVihW5ytILO03Pzza-iBRgcLdELMGmwX3Dvs5DCa9IdONcDB0Z5oo31PeegpY6igqK2NH7jo_II0DbnPuREZ2tnMJUyBIjHtzFcCwz_u-SnCViUxRL7LGnmRm_sMpNJhh3uq4wfGC7VJsylanlAEnY5OQ5U2mVuLJNFVd3MasjFP6ix7PEj-lGOTvdh9aVk29_j39me1rBM8hJRZUbkptuuEsvcI7dB8Ntm9Uva7B3IhPcTEfpMFe1qx20ANvvdX8tkX2-hbctEJ6ZnOnv4kZYls8jctf_Cf-5-yK8NJfJwcvx29e8iu0qqlOIpHrLFZbc1jhF2b9El1Zn4Cj7siog |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1tb9MwELamTpqQEOKdbrwcEsongpI4TmKkfKialjFoN6kdbJ8ix3GhWptUfQHt5_BPOTtJoQwh0S-tZNepeue753zn5wh5lSuZT6hH7UgoBwMUtIPcm1AbsQBnUoaSG0kPhsHxuX9ywS72SJMx1ZfPVos3-s2Yaf1Bt8PRceE4PhlZ3VE3vrSGvc-jeGiddd71zDG1LpKwzpJ-fG0lcfltsraS07jhZxwkFUlh9fK4z9Fk70cRut4W2T_91Oslv_IOYdUGl9HAZjzwG56ivy-z68tuANSbdZa3v5c6B766MiXwvzmy_l1yp0ag0KlU5h7ZU8V9cjCoc-wPyI9xU3sO5QTmCuH1XEB2DQLwv8JA2shSj01N-buCxQb9aw4zHeeDPtiFprIASrRIc3yamQLr7Tk-iCIH0x_Qnk2vFBh1RF2GJbrH6RJyU55bfHkLHZDoaEHvFLUCw4b7kJz3e-PusV03crClzxy08xmNfKGUvljkSBWEHjrBMMsiGlCqWI72Nvc0tkB0ppw8EAzDQOoHGcJXwTFUfkRaRVmoJwS4kJFLfeEGofIjqbJ8ghYoYqHryiwSWZt4jUhSWbOc62Ybs7TJtg-S9E85tsnr7ZcWFcnHv6e_bGSd4mbUGRZRqHKzSnUWHyEemtE2eVzJfrsgZdxHbBy0SbijFdsJmuh7d6SYfjWE35wyN9Jr2jv6k1ZXZc3vYyH30OJ5HkYAzHAFMOfwP-e_IAe4h9KP74cfjsgtPWgqHdlT0lovN-oZoq919rzeMj8BNWAkPg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Treatment+of+melasma+by+a+combination+of+intense+pulsed+light+with+advanced+optimal+pulse+technology+and+human-like+collagen+repair+dressing%3A+A+case+series+study&rft.jtitle=Medicine+%28Baltimore%29&rft.au=Chen%2C+Juping&rft.au=Liu%2C+Jun&rft.au=Wu%2C+Jianhong&rft.date=2022-08-05&rft.issn=1536-5964&rft.eissn=1536-5964&rft.volume=101&rft.issue=31&rft.spage=e29492&rft_id=info:doi/10.1097%2FMD.0000000000029492&rft.externalDBID=n%2Fa&rft.externalDocID=10_1097_MD_0000000000029492 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1536-5964&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1536-5964&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1536-5964&client=summon |